Scenic Biotech, an Amsterdam, the Netherlands-based therapeutics company, raised €6.5m in Series A financing.
The round was co-led by Netherlands-based life sciences investor BioGeneration Ventures (BGV) and INKEF Capital, with the participation of Oxford Sciences Innovation (OSI), the university venturing investor of Oxford University.
The company will use the funds to develop its genetic off-switch for cancer and rare genetic diseases.
Coming out of Oxford University and Netherlands Cancer Institute, Scenic is using technology to unlock the power of genetics to overcome cancer and other diseases. Cell-Seq, the company’s underlying technology focuses on disease suppressing genes, which until recently have proved problematic to uncover.
The company was co-founded by Thijn Brummelkamp, Professor at the Netherlands Cancer Institute, and Sebastian Nijman, Associate Professor of the Ludwig Institute for Cancer Research at Oxford University.